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mdanderson.org (Jean-Pierre J. Issa).There is compelling evidence to support the importance of DNA methylation alterations in cancer
development. Both losses and gains of DNA methylation are observed, thought to contribute patho-
physiologically by inactivating tumor suppressor genes, inducing chromosomal instability and
ectopically activating gene expression. Lesser known are the causes of aberrant DNA methylation.
Recent studies have pointed out that intrinsic gene susceptibility to DNA methylation, environmen-
tal factors and gene function all have an intertwined participation in this process. Overall, these data
support a deterministic rather than a stochastic mechanism for de novo DNA methylation in cancer.
In this review article, we discuss the technologies available to study DNA methylation and the
endogenous and exogenous factors that inﬂuence the onset of de novo methylation in cancer.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Understanding what drives cancer has been profoundly affected
by the detailed analysis of the genome of multiple neoplasias, in
some cases in single-base pair resolution [1–3]. These recent pro-
jects were made possible by the Human Genome Project; indeed,
as predicted, the quest to sequence the human genome supported
the development of new sequencing and computational methods
[4]. As we learned, the results of the Human Genome Project and
the new methods it promoted revolutionized the genomics ﬁeld
and supported the development of yet more advanced techniques,
the most prominent of which at this moment are the massively
parallel sequencing techniques [5]. As result, the discovery of
new mutations that explain particular diseases (not only cancer
but also inherited pathological conditions, as well as genotypes
predisposed to develop such conditions) is achieved with extraor-
dinary reduction in cost and time. The study of the human epige-
nome, referring to speciﬁc chemical modiﬁcation of DNA or
chromatin proteins, is also beneﬁting from these new technologies.
Of special interest in cancer biology is the study of DNA methyla-
tion. While there is no question that cataloguing abnormally meth-
ylated gene promoters (along with other regions with regulatory
function) is very necessary and will likely reveal important players
in tumor biology, another pressing question is what drives cells to
gain or to lose such a mark. In this review, we will discuss recent
advances in mapping DNA methylation, the genomic compart-
ments where it occurs and their biological relevance, and thecal Societies. Published by Elsevier
(M.R.H. Estécio), jpissa@possible causes of the high incidence of aberrant methylation in
certain tumors.
2. Fine combing DNA methylation
The epigenome in genome-wide scale is still understood to a
lesser degree of detail than the genome sequence. One reason is
that there are as many epigenomes as cell types; although the bulk
of DNA methylation changes little from one tissue to another, the
fraction that changes profoundly impacts cell differentiation and
disease [6–11]. Another reason for the relative lack of detailed
mapping of the epigenome is that it cannot be directly measured.
DNA methylation status, for example, is not revealed by direct
sequencing and thus depends on additional manipulation [12].
This has resulted in studies of a small fraction of the genome per
experiment, analyses that are qualitative rather than quantitative,
and in some cases biased measurements of DNA methylation to
CpG-rich or CpG-poor regions of the genome, according the chosen
method [13,14]. In many instances such biases are desirable, since
it is still beyond the capacity of most laboratories to assay every
single CpG nucleotide. Fortunately, as for genome studies, the
methods to study the epigenome are evolving at a fast pace. The
decreasing cost of high-throughput sequencing promises to make
genome-wide mapping of methylated cytosines using bisulphite-
treated DNA as template [15,16] accessible to a larger number of
research groups. Also, new sequencing technologies have reported
the direct discrimination of modiﬁed dinucleotide bases with a cer-
tain degree of accuracy [17].
Our understanding of the human methylome (both in normal
and cancerous cells) has evolved throughout the years, reﬂecting
both the introduction of new technologies and the description ofB.V. Open access under CC BY-NC-ND license.
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ated CpG sites. As for technological advances, the single most
extraordinary breakthrough was the introduction of bisulphite-
treatment [12], which moved the ﬁeld from inaccurate estimates
based on Southern blot analysis [18] to accurate, quantitative anal-
yses. Most important, DNA bisulphite-treatment ﬁnally allowed a
positive identiﬁcation of individual methylated CpG sites using
the polymerase chain reaction (PCR). Thus, bisulﬁte-based meth-
ods also made possible the study of DNA available in small
quantities or of poor quality, like those obtained from frozen or
parafﬁn-embedded tissues. Throughout the years, the technology
to study single genes moved from qualitative (methylation-speciﬁc
PCR [19]), to semi-quantitative (COBRA, Q-MSP, among other
methods [20,21]) and highly quantitative (pyroMeth [22,23])
assays. All these assays were designed to study discrete genomic
regions, covering a few hundred base pairs at a time (bisulphite-
sequencing) but mostly evaluating a few CpG sites of a single gene
per experiment. As a consequence, the studied genes were selected
a priori based on function or genomic location, and tumor suppres-
sor genes were the prime candidates. This biased selection of genes
resulted in the commonly accepted concept that DNA methylation
is an alternative damage to genetic mutations in tumor suppressor
genes; that DNA methylation has a result similar to inactivating
mutations is true, but DNA methylation targets other molecular
functional categories, as well. Also, not all tumor suppressor genes
are targeted by DNA methylation. This topic is discussed in further
detail in the next sections of this review.
In the same way that global proﬁling of gene expression is a bet-
ter strategy to identify molecular signatures of tumor subtypes and
clinical outcome, large-scale DNA methylation is also more power-
ful, mainly when critical markers are unknown for the disease of
interest. One of the ﬁrst attempts of genome-wide (or at least
large-scale) methylome analysis adapted a previously published
method to detect copy number changes [24]. In this method, after
serial digestion of DNA with methylation-sensitive and insensitive
restriction enzymes, methylated fragments could be detected as
missing signals in two-dimensional gel analysis [25,26]. We
learned from this method that a large number of genes (on average
5%) are hypermethylated in cancer, and more tumor-speciﬁc mark-
ers were identiﬁed in this process [27]. The fact that assigning a
genomic position to each identiﬁed differentially-methylated tar-
get is somewhat labor-intensive (the method required gel-extrac-
tion and cloning of fragments of interest) was an obstacle to its
incorporation in routine analysis. Other methods with similar de-
sign become available and again were adopted by a few groups,
sometimes limited to the original developers of the method [28–
30]. In a short period of time, however, several groups indepen-Table 1
Massively parallel sequencing-based methods to study DNA methylation in high coverage
Technique Detection Description
HELP-Seq Restriction enzyme HpaII restriction enzyme is used to e
for unmethylated fragments is comp
MeDIP-Seq Antibody Methylated DNA is captured using a
sequencing. Regions enriched for ca
with little or no quantitative charac
MethylC-Seq Bisulﬁte treatment The genome is fragmented by sonica
conversion. It is the only truly genom
still high cost of the method limits i
the standard for methylome analysi
Padlock, BSPPs Bisulﬁte treatment Genomic DNA is treated with bisulﬁt
The fact that only selected areas are
or a weakness of the method, depen
RRBS Restriction
enzyme + bisulﬁte
treatment
Genomic DNA is fragmented using M
electrophoresis. The puriﬁed DNA is
after library preparationdently developed DNA microarray-based methods to assay DNA
methylation [31–33]. These have the advantage that targets are
known in advance, so labor-intensive cloning and sequencing of
differentially methylated loci is not necessary. With a greater inter-
est in cancer epigenetics, companies developed arrays speciﬁcally
designed to investigate promoter regions and CpG islands (actu-
ally, the ﬁrst adopted arrays to study DNA methylation were de-
signed for ChIP-on-Chip experiments, but the coverage of gene
promoter made these arrays compatible with DNA methylation
studies). A limitation of most methylation-microarray methods is
that they are still qualitative. Nonetheless, hundreds to thousands
of cancer-methylated genes were identiﬁed using these methods,
and they further conﬁrmed the tissue-speciﬁcity and age-related
nature of DNA methylation [34,35].
The most recent developments in methylome analysis resulted
from massively parallel sequencing techniques. All methods used
to generate methylation libraries suitable for microarray analysis
can be directly or with slight modiﬁcations applied to each of these
platforms (thus meDIP has become meDIP-Seq, HELP has became
HELP-Seq, and so on; Table 1). Due to the complexity of mamma-
lian genomes and the high-cost associated with single-base
mapping of methylated cytosine, most groups employ reduced-
representation libraries to study the epigenome [36,37]. The only
truly genome-wide mapping of methylated cytosines in humans
has been performed for normal cells [16,38], but similar maps of
adult cells and of the cancer epigenome will certainly become
available soon. Once again, despite the increase in coverage, the
results are in concordance with what has been previously reported:
promoter CpG islands are in their vast majority unmethylated in
normal cells, and gene body methylation correlates positively with
gene expression. As novel ﬁndings, a difference in CpG methylation
between exon and intron regions raises the possibility that gene
body methylation participates in splicing regulation. Also, the pres-
ence of non-CG methylation (which occurs mostly in the CHG and
CHH contexts) in the human genome was reported by Lister et al.
[16] when proﬁling the methylome of ES (embryonic stem) cells.
Non-CpG methylation is well documented in plants and although
it has been previously reported for individual genes in mouse ES
cells [39,40], the discovery of non-CG methylation mark in such
high frequency in the human genome (up to 25% according to Lis-
ter et al.) was surprising. Supporting a possible functional role,
non-CG methylation showed different distribution between gene
bodies (enriched) and regulatory regions (depleted), and is virtu-
ally lost during differentiation. There is limited information about
non-CG methylation in the cancer methylome [41,42] and more
studies are necessary to resolve its prevalence and physiological
consequence.or whole-genome resolution.
Ref.
liminate the methylated fraction of the genome, and the enrichment
ared to DNA digested with MspI
[133]
nti-5-methylcytosine antibodies, followed by massively parallel
ptured tags are classiﬁed as methylated, rendering qualitative maps
teristics
[134]
tion, and modiﬁed adaptors are ligated to the DNA prior to bisulﬁte-
e-wide method applied to the human genome at the moment, but the
ts application to large group of samples. This technique may become
s with the introduction of cheaper, faster sequencers
[16]
e, and selected targets are collected using molecular inversion probes.
evaluated in high depth for DNA methylation can be either a strength
ding on the researcher’s objective
[58,135]
spI, and fragments of a certain size range are puriﬁed from gel
ligated to modiﬁed adaptors, bisulﬁte-treated, and then sequenced
[36]
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methylation analysis was the development of bisulphite-treat-
ment, the next breakthrough will be the acquisition of information
of chemically modiﬁed nucleotide bases (not only 5-methylcyto-
sine, but also the recently rediscovered 5-hydroxymethylcytosine)
at the same time as collecting sequence information. New sequenc-
ing technology yet in development follows the dynamic of dinucle-
otide incorporation in real-time and records the brief stalling of
DNA polymerase when it encounters modiﬁed DNA bases [17].
Competing technology using nanopores is also in development
[43]. Both methods have only been validated for short synthetic
pieces of DNA and need more optimization before routine use for
DNA methylation analysis.
3. Location, location, location
Depending on where it is located, DNA methylation causes (or
correlates with) different biological outcomes. In a very simplistic
way, the genome of most species can be divided into two major
compartments based on the DNA composition: single-copy DNA
(represented by exons, introns and other non-repetitive DNA)
and repetitive DNA (whose main components in humans are retro-
transposons of the SINE and LINE classes) [44,45]. This natural divi-
sion of the genome was described well before more detailed DNA
sequencing maps were available [46,47]. Genes, or transcriptional
units, are also better studied regarding the effect of DNA methyla-
tion on their transcriptional capability when divided into promoter
region and gene body. Finally, gene promoters must be categorized
as CpG island and non-CpG island promoters. Fig. 1 graphically
represents these genomic locations, and how DNA methylation re-
lates to function is summarized in Table 2.
Starting this discussion with repetitive DNA of transposon and
retrotransposon kinds, we can appreciate the important role of
DNA methylation in maintaining the genome stability. Repetitive
elements of SINE (Small Interspersed Nuclear Element), LINE (Long
Interspersed Nuclear Elements), LTR (Long Terminal Repeat) and
DNA classes originate from DNA or RNA viruses, and also from
our own genome mRNA and tRNA molecules which acquired the
capacity to replicate independently of the host genome, and toFig. 1. Graphic representation of the different compartments where DNA methylatio
retrotransposons are shown in the ﬁgure to represent the repetitive DNA compartment
Table 2
DNA methylation in different genomic compartments in normal and cancer and its conseq
Compartment Methylation in normal
Promoter CpG
island
1–2% methylated, corresponding to X-inactivation, imprinting
and germ cell speciﬁc expression
Non-promoter
CpG island
Variably methylated, often tissue speciﬁc
non-CpG island
promoter
Methylated or unmethylated
Gene body Methylated in active genes
Retrotransposons Mostly methylatedmove freely with the help of specialized proteins with endonucle-
ase and ligase functions. Our discussion here will be limited to
these kinds of repeats. Evolutionary and molecular studies of mul-
tiple species are concordant with an initially explosive activity of
these elements, resulting in both an increase in genome size and
reshaping both in cis (by introducing new sequences of few bases
to several kilobases in length) and in trans (by promoting recombi-
nation of different loci intra- and inter-chromosomes) of the gen-
ome [48]. Clearly, the result of their activity was increased
diversity, the prime material of selective events [49]. Indeed, it is
well accepted that the current pattern of gene expression is
strongly inﬂuenced by past reshaping of the genome by transposi-
tion events. However, deleterious effects make it impossible for
any cell type or organism to endure massive activity of mobile ele-
ments, and these elements were selectively repressed by DNA
methylation and other epigenetic modiﬁcations. Genome-wide
and repeat-speciﬁc studies show that the vast majority of SINE,
LINE, LTR and other repetitive elements are DNA methylated. Thus,
due to their high coverage of the human genome, the bulk of meth-
ylated CpGs are in this compartment [50]. It is not entirely clear
how the cell machinery recognizes repetitive from non-repetitive
DNA. The enzyme LSH (Lymphoid-Speciﬁc Helicase) was identiﬁed
as important in the maintenance of DNA methylation of repetitive
elements and thus dubbed a ‘‘heterochromatin guardian’’ [51,52],
but further evaluation of knockout models of this enzyme showed
an action not only in repetitive DNA, but also single-copy genes
[53]. Extensive reports have highlighted that DNA methylation of
repetitive elements is frequently disrupted in cancer [54,55], caus-
ing genomic instability [56] and activation of oncogenes [57].
Gene bodies represent another methylation-rich compartment
of the human genome. Contradicting the dogma that DNA methyl-
ation correlates with repressed states, gene body marking is found
in actively transcribed genes, as measured by mRNA expression
[58–60]. This so-called DNA methylation paradox was elegantly
addressed in the late nineties [61], and the proposed explanation
implied that the sliding of RNA polymerase over the gene body at-
tracted DNA methyltransferase enzymes. Notably, this insightful
proposal was done before the currently well-documented elonga-
tion-dependent marking of H3K36me3 in gene bodies [62]. Son occurs in relation to CpG islands and genes. For clarity, only SINE and LINE
.
uence.
Methylation in cancer Consequence
Increase methylation of
1–10% of loci
Gene silencing
Increased methylation Unknown
Methylated or
unmethylated
Associated with expression but may be secondary
to transcription programs
Poorly studied May be secondary to transcription programs
Frequently
hypomethylated
Chromosome instability
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quence of transcription, rather than an active agent in promoting
it. However, not much work has been done to mechanistically ad-
dress this question. Thus the conclusion that intragenic non-pro-
moter DNA methylation simply follows gene expression may
change. A recently published study proposes that DNAmethylation
excludes Polycomb group (PcG) protein binding to DNA, maintain-
ing histones free of H3K27me3 and thus facilitating transcription
[63]. Another feature of gene body DNA methylation is an apparent
higher DNA methylation of exonic compared to intronic regions,
leading to a discussion on whether this marking facilitates splicing
[64].
Proximal gene promoters comprehend in general the positions
1 kb to +0.5 kb from transcription start sites. Nearly 70% of the
proximal promoters overlap with a CpG island; structurally, these
promoters differ by being typically TATA-less. As discussed before,
CpG island promoters are also typically methylation-free in normal
cells, with less than 3% of them being methylated. An absence of
methylation does not imply promoter activity, and consequently
it does not explain tissue-speciﬁc differences in gene activity. Thus,
gene promoter methylation has been ruled out as the main force
behind cell lineage differentiation. However, methylated promot-
ers are always repressed, at least in natural conditions. Non-CpG is-
land promoters (or CpG-poor promoters) are found methylated in
normal tissues, and the link between transcriptional repression
and DNA methylation is less clear in this class of promoters: in
many examples, active genes have methylated CpG-poor promot-
ers. Right there lays the main difference between CpG island and
non-CpG island promoters: The different regulatory potential of
DNA methylation in promoter activity. Thus, CpG island promoters
are the most straightforward compartment to evaluate when
searching for aberrant DNA methylation in cancer and speculating
as to its involvement in disease initiation and progression, and the
knowledge acquired from these studies were summarized in the
previous section. Naturally, similarly to genetic alterations, most
of de novo DNA methylation in cancer occurs as passenger altera-
tions. However, in many cases DNA methylation affects genes with
an important role in tumorigenesis and thus is a driver force in the
disease [65,66]. Once established, DNA methylation in CpG islands
is stably transmitted to daughter cells. The only well-documented
natural reversion to a demethylated status occurs after fertiliza-
tion, where active erasure of DNA methylation is observed in the
paternal DNA, and passive demethylation of maternal DNA [67].
It is still unknown whether the hypomethylation of repetitive ele-
ments in cancer occurs through an active or passive mechanism.
Inhibition of DNA methylation by drug treatment can reduce the
levels of DNA methylation genome-wide, but never to complete
erasure of this mark [68]. This has proved a powerful therapeutic
approach, particularly in hematopoietic malignances, which have
a high rate of disease remission [69,70]. Upon drug withdrawal,
re-methylation of repetitive elements and other normally methyl-
ated regions occurs relatively fast, suggesting that DNA methyla-
tion is closely monitored by cellular mechanisms of homeostasis.
Again, CpG-poor promoters behave differently: in the cases where
DNA methylation occurs together with a repressed status, forced
gene re-expression followed by demethylation can be achieved
by increasing the concentration of transcription factors [71].
CpG islands are also found outside gene promoters, occurring
both in inter- and intragenic regions. The function of these CpG is-
lands is less well known, but their overlap with conserved regions
among different species suggests that they may be part of distal
regulatory regions and enhancers. Their pattern of DNA methyla-
tion in normal and cancer resemble that observed for promoter
CpG islands, but with a higher frequency of methylation in normal
cells. Also, a fraction of inter- and intragenic CpG islands may rep-
resent promoter regions of unknown transcripts, or an alternativetranscription start site of tissue-speciﬁc (or developmental stage-
speciﬁc) gene variants. In a comprehensive analysis to determine
the characteristics of intragenic CpG islands, it was found that they
frequently overlap with capped mRNAs and, in further validation
steps, novel gene transcripts were discovered to initiate in these is-
lands [72].4. DNA hypermethylation in cancer
Despite the lack of a large collection of samples from normal or
diseased tissues proﬁled in genome-wide scale for DNA methyla-
tion, we have learned from single-gene studies that de novo DNA
methylation of promoter CpG islands is a frequent alteration in
cancer, resulting in transcriptional silencing of dozens to hundreds
of genes per tumor [73,74]. Even with a biased selection of genes,
DNA methylation proﬁling in normal and tumor tissues revealed
some interesting patterns. Except for imprinted and X-chromo-
some inactivated genes, promoter CpG islands are very rarely
methylated in normal tissues, but many show tissue-speciﬁc gains
of methylation in cancer [75,76]. In a given tissue type, some tu-
mors show very little DNA hypermethylation while others display
concordant hypermethylation of a subgroup of genes that cannot
be explained by chance and thus represent a hypermethylation
phenomenon, termed CIMP (CpG island methylator phenotype)
[77]. It has also been reported that aging is an important factor
in epigenetic instability, as a linear increase in DNA methylation
in promoter CpG islands has been observed when comparing nor-
mal tissue specimens from young and old donors [78]. Paradoxi-
cally, global levels of DNA methylation appear to be reduced in
cancer and older individuals [79]. When studied in patients with
different disease outcomes, DNA methylation was also found to
be a strong predictor of survival. This relationship was not one-
way, though: an increased frequency of methylated genes was
found to be a marker of poor prognosis in colorectal cancers and
in some leukemia subtypes [77,80–83], but highly methylated
cases showed better prognosis in acute myeloid leukemia [84].
A very important conclusion from single-gene analysis was that
many silencing events have a driver function in cancer, or at least
signiﬁcantly modulate the tumor biology. Promoter DNA methyla-
tion of the CDKN2A gene, likely the most famous example of an
epigenetically silenced gene in cancer, also has biological conse-
quences with a tumorigenic potential. The protein product of the
short isoform coded by the cdkn2a locus is a potent tumor sup-
pressor gene, and it was known to be deleted in many solid tumors.
The report that DNA methylation was the cause of its inactivation
in a relatively large fraction of solid tumors [85] gave credence to
the idea of hypermethylation as the ‘‘second hit’’ in Knudson’s tu-
mor suppressor gene inactivation model. In practice, however,
ﬁnding one allele inactivated by DNA mutation and the other allele
hypermethylated is not as frequent as ﬁnding both alleles hyper-
methylated. Another good example of a hypermethylated driver
gene is MLH1. Inactivation of this gene by promoter DNA methyla-
tion is observed in virtually all sporadic microsatellite unstable
colorectal tumors, and further investigation conﬁrmed MLH1 loss
as the cause of microsatellite instability in these tumors [86,87].
These and many other ﬁndings suggest that, similar to genetic
mutation, many DNA methylation events are drivers in
tumorigenesis.
5. Nothing random about it
As mentioned in the previous sections, methylation errors in
cancer have been extensively documented, and the introduction
of genome-wide analytical methods has conﬁrmed that both gain
and loss in DNA methylation are frequent events in cancer. Also,
Fig. 2. Factors that inﬂuence de novo DNA methylation in cancer.
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particular proﬁles are associated with clinico-pathological states
[88–92]. More elusive is the origin of such alterations. What has
become clear is that aberrant DNA methylation is not a random
event, since only a subset of genes is affected by this modiﬁcation.
Several factors (both endogenous and exogenous) have been linked
to abnormal DNA methylation – some discovered in correlative
and epidemiological studies, others in well-controlled in vitro
experiments (Fig. 2). Some of these factors are summarized here.
5.1. Gene microenvironments
Initial reports of silencing of tumor suppressor genes by DNA
methylation generated the perception that silencing mechanisms
target preferentially certain functional categories. DNA methyla-
tion was understood as a random process, and growth advantage
and clonal selection of cells with certain hits dictate the ﬁnal ob-
served methylome. The discrepancy in methylation-predisposition
among genes with virtually identical cellular functions (e.g. MLH1
vs. MSH2) clearly indicates that selection does not universally ex-
plain all promoter hypermethylation. A deterministic model
gained force with the description of genetic and chromatin signa-
tures associated with gene predisposition to DNA methylation in
cancer. In a comprehensive search for DNA signatures associated
with gene predisposition to DNA methylation, Feltus et al. [93] de-
scribed seven short DNA motifs which discriminate frequently
methylated genes from others that are predominantly resistant
to de novo methylation in cancer. Short DNA motifs were also
shown to occur in different frequency between genes methylated
in the cancer cell lines CaCo2 (colon) and PC-3 (prostate) [94].
Although the mechanism by which short DNA motifs are asso-
ciated with protection from DNA methylation is not revealed in
the previous works, it is possible that they are binding sites for
proteins with insulator functions. A large part of the genome is
constitutively maintained in a repressed state, not only by DNA
methylation but also by histone modiﬁcations, for example
H3K9me3 and H3K27me3. Repressed chromatin is conﬁned in part
due to the presence of insulator and blocking elements, for exam-
ple CTCF and USF1/2 proteins [95,96]. Genes located close to
euchromatin/heterochromatin boundaries are subject to position-
effect variegation, and it has been proposed that, upon weakening
or elimination of boundaries, heterochromatin would spread andcause silencing of adjacent genes [97]. Thus, pockets of methylated
DNA (or condensed chromatin) would act as methylation/nucle-
ation centers. Indeed, heterochromatin spreading is a well-de-
scribed phenomenon in yeast and plants, and it involves the
participation of inverted repeats and non-coding RNA [98,99]. In
mammalian cells, the involvement of non-coding RNA in DNA
methylation has not been conﬁrmed. However, DNA methylation
spreading from repetitive DNA was seen in mouse cells, using engi-
neered plasmids to mimic the mouse aprt loci [100]. Paradoxically,
we recently found that promoter CpG islands located in genomic
regions rich in retrotransposons are resistant to de novo methyla-
tion in cancer [101], and that this marking is both complementary
to and independent of other genetic and chromatin signatures, like
the presence of short DNAmotifs and PcG protein marking. It is un-
likely that a simple unifying signature of methylation exists;
rather, various predictors need to be reconciled in a multivariate
mode with weighting scores. Also, a differentiation should be made
between models that explain DNA methylation across tissues
types, and those that will clarify, for example, why the p15 gene
promoter is methylated in hematological malignancies but very
rarely in solid tumors. Finally, these signatures must be understood
as the basis upon which Darwinian selection works. In other
words, selective events modify gene predisposition; indeed, meth-
ylation-prone oncogenes identiﬁed in by our predictive model are
not found methylated in cancer (unpublished observations).
5.2. Transcriptional programs
A distinctive feature of DNA methylation in cancer is its relative
tissue-speciﬁcity. Thus, features other than DNA sequence must
play a role in predisposition or resistance to silencing by methyla-
tion in cancer. Transcriptional programming evidenced by basal
levels of gene expression and/or chromatin patterns in normal tis-
sues may be revealing in this case. The prototypical example is pro-
moter marking by PcG proteins such as Eed and Suz12, and the
resulting H3K27me3 in embryonic stem (ES) cells. After the initial
description of genome-wide targets of these proteins in human
embryonic stem cells [102], three groups independently reported
that genes targeted by PcG proteins are more frequently targeted
by DNA methylation in cancer [103–105]. Further dissection of
PcG marking and DNAmethylation revealed that these two distinct
silencing events occur more frequently alone than in combination
in cancer [106], a ﬁnding conﬁrmed by others and named ‘‘epige-
netic switch’’ to describe the exchange of H3K27me3 mark in gene
promoters in normal tissues by DNA methylation in cancer [107].
The mechanism behind epigenetic switching is still unknown.
However, the fact that chromatin marks in ES cells predict DNA
methylation in cancer supports the idea that aberrant DNA meth-
ylation does not occur randomly, and can be linked to tissue-spe-
ciﬁc epigenetic states in normal tissues.
5.3. Cellular and host factors
Gene speciﬁcity and transcriptional programs account for some
of the fundamental patterns of aberrant DNA methylation in can-
cer, but cannot explain patient to patient variability in the process
within a given tumor type. Thus, there must be some cellular and
host factors (in addition to selection) that shape the eventual can-
cer methylome. Known mediators of epigenetic variability include
aging, inﬂammation and exposures, and there are likely several as
yet unknown factors as well.
Aging is undoubtedly the most important risk factor associated
with adult human malignancies. The classical interpretation is that
association occurs due to increased exposure to environmental car-
cinogens and accumulation of genetic mutations. From this point
of view, it seems logical that the longer one survives, the higher
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regulatory genes. Both the DNA sequence and the epigenome
change with aging. A decrease in DNA methylation content during
aging was reported more than two decades ago [108], and such
alteration occurs mostly through a loss of methylation in inter-
genic and interspersed retroelements. The lack of convincing data
supporting a correlation between decreased methylation in aging
and increased gene expression has undermined the oncogenic
potential of such alterations. However, some recent evidence in
colon cancer supports a role for global demethylation in the
increased rate of chromosomal abnormalities, and in the activation
of oncogenes [57,109]. Historically, the surprising discovery that a
gain in methylation of single-copy CpG islands also occurs during
aging gave a fresh view on this subject [78]. In this case, increased
methylation in gene promoters can account for reduced gene
expression. This process was thought to be far less widespread
than hypomethylation, with a few genes identiﬁed after much
search. However, the use of genome-wide methylation proﬁling
of young and old mice revealed that more than 700 genes show
age-related methylation [34]. Notably, according to similar studies
done in humans, there is a large overlap among genes hypermethy-
lated as a consequence of aging and tumorigenesis, suggesting a
mechanistic link between these processes [110–112]. It is impor-
tant to note that aging is partially due to the accumulative number
of cell replications and, from this angle, cancer cells are the ulti-
mate old cell, either in vivo or in vitro. Thus, aging accounts for a
large fraction of epigenetic variation in normal tissues, and can also
explain some of the variation seen in cancerous tissues as well.
Inﬂammation and chronic diseases are also predisposition fac-
tors to cancer formation. For example, the risk of gastric cancer is
higher in individuals with chronic gastritis compared to those
without gastritis, and infection by Helicobacter pylori is the most
common cause of gastric and duodenal ulcers [113]. Other patho-
gens are also implicated in cancer development, for example HPV
in cervical carcinomas, and HBV and HCV in hepatic cancer
[114,115]. Inﬂammation is also the likely mediator of increased
cancer risk in diseases such as Barret’s esophagus and inﬂamma-
tory bowel disease [116]. Also, chemical agents are also well-
known carcinogens; tobacco smoking is the leading cause of lung
cancer, and again inﬂammation of bronchial epithelium contrib-
utes to the carcinogenic potential of this agent [117]. One common
molecular link between all these exposures is aberrant DNA meth-
ylation. A positive relationship between H. pylori infection and
DNA methylation has been seen before cellular transformation of
the gastric mucosa [118–120], and similar observations have been
reported for viral infection and liver cancer [121,122]. Chronic
inﬂammatory states and smoking have both been linked to in-
creased methylation in normal mucosa and/or cancer cells
[123,124]. One possible explanation for these associations is that
the higher proliferation of inﬂammatory tissues inﬂuences the on-
set of aberrant DNA methylation, in the same way that multiple
cell divisions do during aging. Alternatively, epigenetic reprogram-
ming as a direct consequence of viral infection is also possible: the
adenovirus e1a protein has been shown to bind to gene promoters
and cause the recruitment of cellular remodeling complexes, like
p300/CBP [125]. In addition, a link between HBV infection and
down-regulation of mir152, resulting in up-regulation of DNMT1
and consequent hypermethylation of multiple gene promoters
has been recently proposed [126]. The association of inﬂammation
and DNA methylation could provide another explanation for epige-
netic variation in Humans.
The hundreds of reports on de novo methylated genes in cancer
often attribute this to deregulation of the controlling mechanisms
of epigenetic marking during tumorigenesis. However, as dis-
cussed earlier, much of this ‘‘deregulation’’ could be attributable
to stochastic errors in replicating DNA methylation in a subset ofthe genome intrinsically susceptible to such errors. There is limited
evidence or true ongoing deregulation of the DNA methylation
machinery in most cancers. However, large scale studies have
now identiﬁed subgroups of cancers that may in fact have such
deregulation. A hypermethylation phenotype characterized by
simultaneous DNA hypermethylation of multiple genes in the
same tumor specimens was described by Toyota et al. [77], a phe-
nomenon termed CIMP (CpG islands methylator phenotype). In
colorectal tumors, this concomitant hypermethylation of selected
loci (which did not show clear age-dependent methylation and
were thus named cancer-speciﬁc) occurs in 10–40% of the patient
samples, depending on how CIMP is deﬁned. This phenotype is
associated with speciﬁc clinico-pathological features, such as tu-
mor location (predominance of right side lesions), prognosis (CIMP
tumors have a poor outcome, except when affected by microsatel-
lite instability) and molecular characteristics (BRAF and KRAS
mutations are frequent in CIMP tumors) [127]. After this initial re-
port, CIMP has been conﬁrmed in several solid and hematopoietic
malignancies [128–131]. The causes of CIMP are unknown, but it is
quite possible that a major regulator of epigenetic homeostasis is
impaired in these tumors, thus causing true epigenetic instability.
In addition, profound loss of methylation has been identiﬁed in a
small subset of cancers [55], and it appears likely that an epige-
netic regulator is abnormal in these cases as well. Recently, inacti-
vating mutations in DNMT3a were described in some leukemias
[132], and this gene is a candidate to explain profound hypomethy-
lation in some cancers. Thus, in addition to aging, inﬂammation
and exposures, there likely are speciﬁc defects in the epigenetic
machinery that help account for the variation in DNA methylation
observed in cancer.
Despite what has been learned in the past decade, there remain
many unknowns in the ﬁeld. For example, the relation between
histone modiﬁcations and DNA methylation continues to be a rich
avenue of research, particularly given the emerging data on a
plethora of mutations in chromatin regulators in cancer. It will
be interesting to see how these relate to DNA methylation. Simi-
larly, the ideas of constitutional epigenetic defects predisposing
to cancer or of genetic predisposition to epigenetic defects are
beginning to be explored. Finally, the contribution to epigenetics
of lifestyle factors such as diet, exercise or obesity, all of which play
a role in cancer development, remains to be ﬁrmly established.
6. Conclusion
It is an exciting time for methylation studies. The current and
prospective technologies allow for proﬁling of normal and tumor
cells with unprecedented depth and accuracy. Methylome maps
are being compared to maps of histone modiﬁcations, transcription
factors and genetic variants. With correct bioinformatics tools to
mine the meaningful data, we are poised to learn how gene micro-
environments, transcription programs and host factors interact to
inﬂuence the onset of DNA hypermethylation in cancer.
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